Form 4: Pliant Therapeutics CFO Executes Option Repricing

Pliant Therapeutics CFO Keith Lamont Cummings participated in a company-wide stock option repricing program on April 17, 2026.

Summary

• Pliant Therapeutics implemented a board-approved repricing of stock options granted on or before March 1, 2025.
• CFO Keith Lamont Cummings had seven tranches of underwater stock options repriced to an exercise price of $1.33 per share.
• The repricing affects a total of 601,295 options held by the CFO.
• The repriced options are subject to a retention period of 18 months, during which the original exercise price applies if the options are exercised early or if the employee leaves under certain conditions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative signal, as it reflects a necessary adjustment due to a significant decline in the company's underlying stock price.

Positives

• The repricing serves as a retention mechanism for key management personnel by aligning incentive compensation with current market valuations.
• The 18-month retention period ensures that management remains incentivized to stay with the company to realize the value of the repriced options.

Negatives

• Option repricing often signals that previous equity-based compensation has lost significant value due to a decline in the company's share price.
• The action may be viewed by some shareholders as dilutive or as a sign that management is being shielded from the impact of poor stock performance.

Risks

• The company's share price has experienced significant volatility, necessitating a repricing to maintain the effectiveness of equity incentives.
• If the share price does not recover, the repriced options may again become underwater, potentially leading to further compensation challenges.

Future Outlook

The company is utilizing an 18-month retention period to align management interests with long-term performance, suggesting a focus on stability and retention of key leadership during a period of depressed equity value.

Management Comments

• The board of directors approved the repricing for all current employees to ensure equity incentives remain effective.

Industry Context

StockSavvy.ai notes that option repricing is a common, albeit sensitive, practice in the biotechnology sector when share prices face prolonged downward pressure, often used to prevent the loss of human capital to competitors.

Comparison to Industry Standards

• Repricing programs are standard in high-growth biotech firms facing market headwinds to maintain employee retention.
• The 18-month retention period is a standard governance safeguard to ensure the repricing is not merely a windfall for executives.

Corporate Governance

Stakeholder Impact

• Shareholders may experience concerns regarding the dilution of value or the optics of repricing options after a share price decline.
• Employees benefit from the increased likelihood of their equity compensation eventually holding value.

Next Steps

• Completion of the 18-month retention period for the repriced options.
• Ongoing monitoring of share price performance relative to the new $1.33 strike price.

Key Dates

Recommendation

The filing indicates internal efforts to stabilize management retention, but the underlying need for repricing suggests the company is currently facing significant market valuation challenges.

Keywords

Pliant Therapeutics, PLRX, Option Repricing, Executive Compensation, SEC Form 4, Equity Incentive Plan